Benefits of jejunostomy feeding in patients who underwent gastrectomy for cancer treatment

Table 3 Tumour characteristics, cohort N = 172, n (%)

Variables	J + (n = 60)	J - (n = 112)	P value
Adenocarcinoma	47 (79.7)	87 (78.4)	1
Grade of differentiation
Good	5 (10.9)	7 (9)	0.76
Moderate	18 (39.1)	38 (48.7)	0.35
Poor	20 (43.5)	31 (39.7)	0.71
Contingent of independent cells	23 (38.3)	33 (30.3)	0.31
GIST	9 (15.5)	22 (20.2)	0.53
Low risk	1 (11.1)	8 (40)	0.2
Medium risk	1 (11.1)	3 (15)	1
High risk	7 (77.8)	9 (45)	0.13
Tumour ≤ 3 cm	10 (16.7)	20 (18.9)	0.84
T
0	0 (0)	3 (2.7)	0.036a
1	5 (8.3)	12 (10.7)
2	6 (10)	21 (18.8)
3	23 (38.8)	39 (34.8)
4	19 (31.7)	15 (13.4)
N0	18 (32.1)	31 (34.4)	0.86
M0	50 (90.9)	79 (84.9)	0.45
Clear margins	45 (75)	92 (84.4)	0.15
Vascular invasion	25 (43.1)	48 (44)	1
Perineural invasion	27 (46.6)	39 (36.1)	0.24

^aP < 0.05.

A group with jejunostomy (J + group) and a group without jejunostomy (J - group) were compared. GIST: Gastrointestinal stromal tumor.